Cargando…
Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes
Hodgkin’s lymphoma is a rare yet highly curable disease in the majority of patients treated with modern chemotherapy regimens. For patients who fail to respond to or relapse after initial systemic therapies, treatment with high-dose chemotherapy and autologous hematopoietic stem cell transplantation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880200/ https://www.ncbi.nlm.nih.gov/pubmed/35207613 http://dx.doi.org/10.3390/jpm12020125 |
_version_ | 1784659127837917184 |
---|---|
author | Al-Juhaishi, Taha Borogovac, Azra Ibrahimi, Sami Wieduwilt, Matthew Ahmed, Sairah |
author_facet | Al-Juhaishi, Taha Borogovac, Azra Ibrahimi, Sami Wieduwilt, Matthew Ahmed, Sairah |
author_sort | Al-Juhaishi, Taha |
collection | PubMed |
description | Hodgkin’s lymphoma is a rare yet highly curable disease in the majority of patients treated with modern chemotherapy regimens. For patients who fail to respond to or relapse after initial systemic therapies, treatment with high-dose chemotherapy and autologous hematopoietic stem cell transplantation can provide a cure for many with chemotherapy-responsive lymphoma. Patients who relapse after autologous transplant or those with chemorefractory disease have poor prognosis and represent a high unmet need. Allogeneic hematopoietic stem cell transplantation provides a proven curative therapy for these patients and should be considered, especially in young and medically fit patients. The use of newer agents in this disease such as brentuximab vedotin and immune checkpoint inhibitors can help bring more patients to transplantation and should be considered as well. |
format | Online Article Text |
id | pubmed-8880200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88802002022-02-26 Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes Al-Juhaishi, Taha Borogovac, Azra Ibrahimi, Sami Wieduwilt, Matthew Ahmed, Sairah J Pers Med Review Hodgkin’s lymphoma is a rare yet highly curable disease in the majority of patients treated with modern chemotherapy regimens. For patients who fail to respond to or relapse after initial systemic therapies, treatment with high-dose chemotherapy and autologous hematopoietic stem cell transplantation can provide a cure for many with chemotherapy-responsive lymphoma. Patients who relapse after autologous transplant or those with chemorefractory disease have poor prognosis and represent a high unmet need. Allogeneic hematopoietic stem cell transplantation provides a proven curative therapy for these patients and should be considered, especially in young and medically fit patients. The use of newer agents in this disease such as brentuximab vedotin and immune checkpoint inhibitors can help bring more patients to transplantation and should be considered as well. MDPI 2022-01-18 /pmc/articles/PMC8880200/ /pubmed/35207613 http://dx.doi.org/10.3390/jpm12020125 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Al-Juhaishi, Taha Borogovac, Azra Ibrahimi, Sami Wieduwilt, Matthew Ahmed, Sairah Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes |
title | Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes |
title_full | Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes |
title_fullStr | Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes |
title_full_unstemmed | Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes |
title_short | Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes |
title_sort | reappraising the role of allogeneic hematopoietic stem cell transplantation in relapsed and refractory hodgkin’s lymphoma: recent advances and outcomes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880200/ https://www.ncbi.nlm.nih.gov/pubmed/35207613 http://dx.doi.org/10.3390/jpm12020125 |
work_keys_str_mv | AT aljuhaishitaha reappraisingtheroleofallogeneichematopoieticstemcelltransplantationinrelapsedandrefractoryhodgkinslymphomarecentadvancesandoutcomes AT borogovacazra reappraisingtheroleofallogeneichematopoieticstemcelltransplantationinrelapsedandrefractoryhodgkinslymphomarecentadvancesandoutcomes AT ibrahimisami reappraisingtheroleofallogeneichematopoieticstemcelltransplantationinrelapsedandrefractoryhodgkinslymphomarecentadvancesandoutcomes AT wieduwiltmatthew reappraisingtheroleofallogeneichematopoieticstemcelltransplantationinrelapsedandrefractoryhodgkinslymphomarecentadvancesandoutcomes AT ahmedsairah reappraisingtheroleofallogeneichematopoieticstemcelltransplantationinrelapsedandrefractoryhodgkinslymphomarecentadvancesandoutcomes |